HHS skips 2026 penalty adjustment
Plus: FDA approves Hibsago for hepatitis B. The day's rules, money, and enforcement, sourced and tiered below.
Plus: FDA approves Hibsago for hepatitis B. The day's rules, money, and enforcement, sourced and tiered below.
|
American Health Intel
Rules · Money · Medicine · Decoded daily
|
| The Regulator |
Wednesday, October 21, 2026 |
|
|
HHS skips 2026 penalty adjustment
|
|
Plus: FDA approves Hibsago for hepatitis B. The day's rules, money, and enforcement, sourced and tiered below.
|
|
|
Rule Confidence: High
HHS will not raise its civil monetary penalty amounts for 2026. Federal penalties on health care providers and plans stay at 2025 levels, per a notice in today's Federal Register.
The notice cites Office of Management and Budget guidance from April 17 saying there is no cost-of-living adjustment this year. It does not change False Claims Act damages or settlement practice.
|
Why it matters
Federal penalty ceilings for health care violations stay where they were last year. Watch whether the full notice lists which penalty categories are covered.
|
|
|
Approval Confidence: High
The FDA approved GSK's Hibsago, the first antisense drug for chronic hepatitis B. In trials, 24% of patients could stop their existing antiviral medicine versus none on placebo.
A 24-week injection added to current therapy. 19% still had the virus controlled 24 weeks after stopping all treatment. Boxed warning for liver reactions and low platelets. No price or patient count released.
|
Why it matters
This is the first antisense drug approved for chronic hepatitis B and aims at a treatment-free period, which is new. Price and U.S. patient count are not yet public, so watch for both.
|
|
|
Also today
FDA final guidance on drug apps Read
First generic Climara Pro patch Read
Virginia Negril Medicaid settlement Read
|
1043 Records | $62.4B Enforcement | 44 Deadlines | 297 Rules |
|
|
Pick your field on the site and every story tells you what it means for you.
|
|
Reply to this email and tell us what you want covered. We read everything.
|
|
We show our work. We score our own calls.
News and analysis, not legal, medical, coding, or investment advice.
You subscribed at americanhealthintel.com · Unsubscribe
|
|